Novo Nordisk's CagriSema associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost

Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications